ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.95
-0.10 (-3.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.05
Open3.05
Bid0.00 x 47300
Ask3.30 x 900
Day's Range2.90 - 3.05
52 Week Range1.55 - 5.75
Volume415,302
Avg. Volume777,259
Market Cap178.77M
Beta1.73
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateOct 30, 2017 - Nov 3, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of ACRX earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 AcelRx Pharmaceuticals Inc Earnings Call

  • Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
    Zacks7 days ago

    Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?

    Is (ACRX) Outperforming Other Medical Stocks This Year?

  • AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
    PR Newswire8 days ago

    AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

    REDWOOD CITY, Calif., Aug. 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common stock. Including this option exercise, total gross proceeds to AcelRx from the offering of an aggregate 8,363,636 shares at a price to the public of $2.75 per share were approximately $23.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by AcelRx. Ladenburg Thalmann acted as co-manager for the offering.

  • AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks13 days ago

    AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

    AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.26% and -11.57%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    AcelRx Pharmaceuticals: 2Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of 20 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results
    PR Newswire14 days ago

    AcelRx Pharmaceuticals Reports Second Quarter 2018 Financial Results

    - European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings - June 30, 2018 cash and short-term ...

  • ACCESSWIRE14 days ago

    AcelRx Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
    Zacks28 days ago

    CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

    CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

  • AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018
    PR Newswire28 days ago

    AcelRx to announce second quarter 2018 results and provide a corporate update on Thursday, August 2nd, 2018

    REDWOOD CITY, Calif. , July 19, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results ...

  • ACCESSWIRE29 days ago

    Free Technical Research on Medtronic and Three More Medical Equipment Equities

    On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), and MiMedx Group Inc. (NASDAQ: MDXG).

  • Why You Shouldn’t Get Too Excited About AcelRx Pharmaceuticals (ACRX) Stock
    SmarterAnalystlast month

    Why You Shouldn’t Get Too Excited About AcelRx Pharmaceuticals (ACRX) Stock

    Not everyone is excited about AcelRx Pharmaceuticals (NASDAQ:ACRX), which focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. Despite the potential advantages, Oppenheimer analyst Leland Gershell believes the drug maker's products may face challenges with market penetration given: (1) the broad effort to reduce opioids' dominant role in analgesia, (2) the unclear advantage of needle-free delivery in populations who typically get IV access, and (3) the lack of physician familiarity with their active ingredient. Anesthesiologists and other specialists we have spoken with agree that Dsuvia could find some utility for acute pain management, and highlight the palliative care setting (e.g. AcelRx's acute pain drug Dsuvia has a November 3, 2018 FDA action date, in advance of which management expects the agency to hold an Advisory Committee meeting.

  • AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    PR Newswirelast month

    AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    REDWOOD CITY, Calif., July 12, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 7,272,727 shares of its common stock, at a public offering price of $2.75 per share. The gross proceeds to AcelRx from this offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by AcelRx, are expected to be approximately $20 million.  All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about July 16, 2018, subject to the satisfaction of customary closing conditions.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...

  • AcelRx Pharmaceuticals Announces Commencement of Public Offering of Common Stock
    PR Newswirelast month

    AcelRx Pharmaceuticals Announces Commencement of Public Offering of Common Stock

    REDWOOD CITY, Calif., July 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it has commenced an underwritten public offering of shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  All of the shares to be sold in the proposed offering will be sold by AcelRx. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.  H.C. Wainwright & Co., LLC is acting as lead manager for the offering.

  • Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
    Zackslast month

    Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

    Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

  • VIVUS' PAH Candidate Data Positive in Early Stage Study
    Zackslast month

    VIVUS' PAH Candidate Data Positive in Early Stage Study

    VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

  • Aclaris' Alopecia Candidate Gets Fast Track Designation
    Zackslast month

    Aclaris' Alopecia Candidate Gets Fast Track Designation

    The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.

  • Why this Peninsula drug company still is betting on pain for a gain
    American City Business Journalslast month

    Why this Peninsula drug company still is betting on pain for a gain

    FDA regulators rejected its drug-device in October, sending its stock sharply lower. Now this company believes new data, Defense Department and hospital shortages of painkillers could help it score approval in November like it did in Europe last month.

  • AcelRx receives European Commission approval for DZUVEO™
    PR Newswire2 months ago

    AcelRx receives European Commission approval for DZUVEO™

    REDWOOD CITY, Calif., June 27, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the European Commission (EC) has approved DZUVEO (under development in the U.S. as DSUVIA™) for the management of acute moderate to severe pain in adults in medically monitored settings.

  • Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
    Zacks2 months ago

    Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

    Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

  • ACCESSWIRE2 months ago

    Neovasc and Three Additional Medical Appliances & Equipment Stocks on Our Research Desk’s Radar

    This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Top Ranked Momentum Stocks to Buy for June 15th
    Zacks2 months ago

    Top Ranked Momentum Stocks to Buy for June 15th

    Top Ranked Momentum Stocks to Buy for June 15th

  • Benzinga2 months ago

    Analyst: AcelRx Will Address FDA Concerns, Secure Approval This Year

    AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has been slowly recovering from a mid-October plunge following the FDA's issuance of a Complete Response Letter. “Since ACRX obtained a CRL in 2017, the company has addressed the FDA's concerns, and reduced the maximum daily dosage of Dsuvia to 12 doses from 24,” the analyst said.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Southern, AcelRx Pharmaceuticals, International Flavors & Fragrances, Pandora Media, Express Scripts Holding, and United Continental — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southern ...